Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy

Gregory B. Lim

DOI: https://doi.org/10.1038/s41569-024-01044-8

IF: 49.421

2024-05-30

Nature Reviews Cardiology

Abstract:Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy

Ahmad Masri,Rhanderson N Cardoso,Theodore P Abraham,Brian L Claggett,Caroline J Coats,Sheila M Hegde,Ian J Kulac,Matthew M Y Lee,Martin S Maron,Bela Merkely,Michelle Michels,Iacopo Olivotto,Artur Oreziak,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Scott D Solomon,Amy Wohltman,Raymond Y Kwong,Christopher M Kramer,SEQUOIA-HCM Investigators

DOI: https://doi.org/10.1016/j.jacc.2024.08.015

2024-08-28

Abstract:Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and stroke. Aficamten is a next-in-class cardiac myosin inhibitor that reduces outflow tract obstruction by modulating cardiac contractility, with the potential to reverse pathological remodeling and, in turn, reduce cardiovascular events. Objectives: This study sought to investigate the effect of aficamten on cardiac remodeling compared with placebo using cardiovascular magnetic resonance (CMR) and its association with key clinical endpoints in the SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) CMR substudy. Methods: SEQUOIA-HCM was a phase 3 double-blind, placebo-controlled trial for adults with symptomatic oHCM who were randomized 1:1 to 24 weeks of aficamten (dose range: 5-20 mg) or placebo. Eligible participants were offered enrollment in the CMR substudy with studies performed at baseline and week 24. Image analysis was performed in a blinded fashion by a core laboratory. Results: Of the 282 randomized patients, 57 (20%) participated in the substudy, and of those, 50 (88%) completed both baseline and week 24 CMR. Baseline characteristics of the CMR cohort were similar to the overall study population. Of these 50 patients, 21 received aficamten and 29 received placebo. Relative to placebo, patients receiving aficamten demonstrated significant reductions (Δ least-squares mean) in LV mass index (-15 g/m2; 95% CI: -25 to -6 g/m2; P = 0.001), maximal LV wall thickness (-2.1 mm; 95% CI: -3.1 to -1.1 mm; P < 0.001), left atrial volume index (-13 mL/m2; 95% CI: -19 to -7 mL/m2; P < 0.001), native T1 relaxation time (-37 ms; 95% CI: -69 to -5 ms; P = 0.026), indexed extracellular volume fraction (-3.9 g/m2; 95% CI: -7.0 to -0.9 g/m2; P = 0.014), and indexed myocyte mass (-14 g/m2; 95% CI: -23 to -4 g/m2; P = 0.004), while there were no significant changes in LV chamber volumes, LV replacement fibrosis (late gadolinium enhancement mass -0.7 g; 95% CI: -2.9 to 1.6 g; P = 0.54), or extracellular volume (0.7%; 95% CI: -2.2% to 3.6%; P = 0.61). Conclusions: The CMR substudy of SEQUOIA-HCM demonstrated that treatment with aficamten relative to placebo for 24 weeks resulted in favorable cardiac remodeling. These changes, particularly with regard to LV mass, wall thickness, and left atrial size, could potentially lead to reduced cardiovascular events including heart failure and atrial fibrillation with longer follow-up. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

Charles F Sherrod 4th,Sara Saberi,Michael E Nassif,Brian L Claggett,Caroline J Coats,Pablo Garcia-Pavia,James L Januzzi,Gregory D Lewis,Changsheng Ma,Martin S Maron,Zi Michael Miao,Iacopo Olivotto,Josef Veselka,Michael Butzner,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,John A Spertus

DOI: https://doi.org/10.1016/j.jacc.2024.08.014

2024-08-29

Abstract:Background: A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been comprehensively described. Objectives: This study sought to determine the effect of aficamten on patient-reported health status, including symptoms of fatigue, shortness of breath, chest pain, physical and social limitations, and quality of life. Methods: SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) randomized symptomatic adults with oHCM to 24 weeks of aficamten (n = 142) or placebo (n = 140), followed by a 4-week washout. The Kansas City Cardiomyopathy Questionnaire (KCCQ) and Seattle Angina Questionnaire 7-item (SAQ7) were serially administered. Changes in mean KCCQ-Overall Summary Score (KCCQ-OSS) and SAQ7-Summary Score (SAQ7-SS) from baseline to 24 weeks and following treatment withdrawal were compared using linear regression adjusted for baseline scores and randomization strata. Proportions of patients with clinically important changes were compared. Results: Among 282 participants, the mean age was 59 ± 13 years, 115 (41%) were female, and 223 (79%) were White. Baseline KCCQ-OSS (69.3 ± 20.1 vs 67.3 ± 18.8) and SAQ7-SS (72.0 ± 21.0 vs 72.4 ± 18.3) were similar between aficamten and placebo groups. Treatment with aficamten, compared with placebo, improved both the mean KCCQ-OSS (13.3 ± 16.3 vs 6.1 ± 12.6; mean difference: 7.9; 95% CI: 4.8-11.0; P < 0.001) and SAQ7-SS (11.6 ± 17.4 vs 3.8 ± 14.4; mean difference: 7.8; 95% CI: 4.7-11.0; P < 0.001) at 24 weeks, with benefits emerging within 4 weeks. No heterogeneity in treatment effect was found across subgroups. A much larger proportion of participants experienced a very large health status improvement (≥20 points) with aficamten vs placebo (KCCQ-OSS: 29.7% vs 12.4%, number needed to treat: 5.8; SAQ7-SS: 31.2% vs 13.9%, number needed to treat: 5.8). Participants' health status worsened significantly more after withdrawal from aficamten than placebo (KCCQ-OSS: -16.2 ± 19.0 vs -3.0 ± 9.6; P < 0.001; SAQ7-SS: -17.4 ± 21.4 vs -2.5 ± 13.3), further confirming a causal effect of aficamten. Conclusions: In patients with symptomatic oHCM, treatment with aficamten resulted in markedly improved health status, including significant improvement in chest pain-related health status, than placebo. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten

Emmanuel Kokori,Ravi Patel,Gbolahan Olatunji,Abdulbasit Opeyemi Muili,Victor Oluwatomiwa Ajekiigbe,Abdulrahmon Moradeyo,Adetola Emmanuel Babalola,Julia Mimi Kwape,Oluwatobi Omoworare,Nicholas Aderinto

DOI: https://doi.org/10.1016/j.cpcardiol.2024.102802

Abstract:Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), which can lead to left ventricular outflow tract (LVOT) obstruction. Traditional treatments often provide limited symptom relief and may not adequately reduce the LVOT gradient. Myosin inhibitors, such as Aficamten , offer a new therapeutic approach by modulating myocardial contractility and improving symptoms. This paper evaluated the efficacy and safety of Aficamten in patients with symptomatic HCM. We conducted a comprehensive literature review of studies evaluating Aficamten for symptomatic HCM, including clinical trials and observational studies up to July 2024. Data on efficacy, safety, and patient outcomes were extracted and analyzed from a total of 10 studies involving 1,067 patients. Aficamten demonstrated substantial efficacy in reducing the LVOT gradient, with dose-dependent reductions ranging from 3.6 % to 48.6 %. It also improved symptoms, with 82.3 % of patients experiencing reduced left ventricular ejection fraction (LVEF) and notable improvements in New York Heart Association (NYHA) functional class. Exercise capacity was enhanced, as indicated by increased peak oxygen uptake. Safety profiles were generally favorable, though some serious adverse events, such as atrial fibrillation and cardiac dysfunction, were reported. Aficamten was well-tolerated overall, with manageable dose-dependent adverse effects. Aficamten represents a promising advance in the management of symptomatic HCM, offering significant reductions in LVOT gradient and improvement in symptoms and exercise capacity. Its safety profile is generally favorable, although ongoing monitoring is necessary to manage potential adverse effects. Future research should focus on long-term outcomes, comparative effectiveness, and real-world evidence.
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Martin S Maron,Ahmad Masri,Michael E Nassif,Roberto Barriales-Villa,Theodore P Abraham,Michael Arad,Nuno Cardim,Lubna Choudhury,Brian Claggett,Caroline J Coats,Hans-Dirk Düngen,Pablo Garcia-Pavia,Albert A Hagège,James L Januzzi,Ian Kulac,Matthew M Y Lee,Gregory D Lewis,Chang-Sheng Ma,Michelle Michels,Artur Oreziak,Anjali T Owens,John A Spertus,Scott D Solomon,Jacob Tfelt-Hansen,Marion van Sinttruije,Josef Veselka,Hugh C Watkins,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,Iacopo Olivotto,SEQUOIA-HCM Investigators

DOI: https://doi.org/10.1016/j.jacc.2024.09.003

2024-11-05

Abstract:Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined. Objectives: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten. Methods: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient <30 mm Hg and <50 mm Hg, respectively), relief in limiting symptoms (≥1 improvement in NYHA functional class and/or ≥10-point change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score), enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake), and ≥50% reduction in N-terminal pro-B-type natriuretic peptide. Eligibility for septal reduction therapy was also evaluated. Results: At 24 weeks, patients treated with aficamten vs placebo showed significant improvement in limiting symptoms (71% vs 42%), were more likely to have complete hemodynamic response (68% vs 7%), demonstrated enhanced exercise capacity (47% vs 24%), and showed a decrease ≥50% in N-terminal pro-B-type natriuretic peptide (84% vs 8%) (P ≤ 0.002 for all). An improvement in ≥1 of these outcome measures was achieved in 97% of patients treated with aficamten (vs 59% placebo), including 23% on aficamten who achieved all 4 outcomes compared with none in placebo. Among 32 patients receiving aficamten and 29 patients receiving placebo who were eligible for septal reduction therapy, 28 (88%) from the aficamten group were no longer eligible at 24 weeks compared with 15 (52%) from the placebo group (P = 0.002). Conclusions: Treatment with aficamten was associated with substantial improvements across a broad range of clinically relevant efficacy measures. These results underscore the wide-ranging potential of aficamten for treatment of patients with symptomatic oHCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with oHCM [SEQUOIA-HCM]; NCT05186818).
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Sheila M Hegde,Brian L Claggett,Xiaowen Wang,Karola Jering,Narayana Prasad,Farideh Roshanali,Ahmad Masri,Michael E Nassif,Roberto Barriales-Villa,Theodore P Abraham,Nuno Cardim,Caroline J Coats,Christopher M Kramer,Martin S Maron,Michelle Michels,Iacopo Olivotto,Sara Saberi,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Lisa Meng,Amy Wohltman,Fady I Malik,Scott D Solomon,SEQUOIA-HCM Investigators

DOI: https://doi.org/10.1016/j.jacc.2024.08.002

2024-08-24

Abstract:Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM), a phase 3, multicenter, randomized, double-blinded, placebo-controlled study. Objectives: The authors sought to evaluate the effect of aficamten on echocardiographic measures of cardiac structure and function in SEQUOIA-HCM. Methods: Serial echocardiograms were performed over 28 weeks in patients randomized to receive placebo or aficamten in up to 4 individually titrated escalating doses (5-20 mg daily) over 24 weeks based on Valsalva LVOT gradients and left ventricular ejection fraction (LVEF). Results: Among 282 patients (mean age 59 ± 13 years; 41% female, 79% White, 19% Asian), mean LVEF was 75% ± 6% with resting and Valsalva LVOT gradients of 55 ± 30 mm Hg and 83 ± 32 mm Hg, respectively. Over 24 weeks, aficamten significantly lowered resting and Valsalva LVOT gradients, and improved left atrial volume index, lateral and septal e' velocities, and lateral and septal E/e' (all P ≤ 0.001). LV end-systolic volume increased and wall thickness decreased (all P ≤ 0.003). Aficamten resulted in a mild reversible decrease in LVEF (-4.8% [95% CI: -6.4 to -3.3]; P < 0.001) and absolute LV global circumferential strain (-3.7% [95% CI: 1.8-5.6]; P < 0.0010), whereas LV global longitudinal strain was unchanged. Several measures, including LVEF, LVOT gradients, and E/e' returned to baseline following washout. Among those treated with aficamten, improved pVO2 and reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) were associated with improvement in lateral e' velocity and septal and lateral E/e' (all P < 0.03), whereas improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores (KCCQ-CSS) was associated with a decrease in both LVOT gradients (all P < 0.001). Conclusions: Compared with placebo, patients receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function, and several of these measures were associated with improvements in pVO2, KCCQ-CSS, and NT-proBNP. A modest decrease in LVEF occurred yet remained within normal range. These findings suggest aficamten improved multiple structural and physiological parameters in oHCM without significant adverse changes in LV systolic function. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy

James J Hartman,Darren T Hwee,Julien Robert-Paganin,Chihyuan Chuang,Eva R Chin,Samantha Edell,Ken H Lee,Roshni Madhvani,Preeti Paliwal,Julien Pernier,Saswata Sankar Sarkar,Julia Schaletzky,Kristine Schauer,Khanha D Taheri,Jingying Wang,Eddie Wehri,Yangsong Wu,Anne Houdusse,Bradley P Morgan,Fady I Malik

DOI: https://doi.org/10.1038/s44161-024-00505-0

Abstract:Hypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly slowing phosphate release, stabilizing a weak actin-binding state. Binding to an allosteric site on the myosin catalytic domain distinct from mavacamten, aficamten prevents the conformational changes necessary to enter the strongly actin-bound force-generating state. In doing so, aficamten reduces the number of functional myosin heads driving sarcomere shortening. The crystal structure of aficamten bound to cardiac myosin in the pre-powerstroke state provides a basis for understanding its selectivity over smooth and fast skeletal muscle. Furthermore, in cardiac myocytes and in mice bearing the hypertrophic R403Q cardiac myosin mutation, aficamten reduces cardiac contractility. Our findings suggest aficamten holds promise as a therapy for HCM.
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Caroline J Coats,Ahmad Masri,Michael E Nassif,Roberto Barriales-Villa,Michael Arad,Nuno Cardim,Lubna Choudhury,Brian Claggett,Hans-Dirk Düngen,Pablo Garcia-Pavia,Albert A Hagège,James L Januzzi,Matthew M Y Lee,Gregory D Lewis,Chang-Sheng Ma,Martin S Maron,Zi Michael Miao,Michelle Michels,Iacopo Olivotto,Artur Oreziak,Anjali T Owens,John A Spertus,Scott D Solomon,Jacob Tfelt-Hansen,Marion van Sinttruije,Josef Veselka,Hugh Watkins,Daniel L Jacoby,Polina German,Stephen B Heitner,Stuart Kupfer,Justin D Lutz,Fady I Malik,Lisa Meng,Amy Wohltman,Theodore P Abraham,SEQUOIA‐HCM Investigators *,Yuhui Zhang,Haibo Yang,Chunli Shao,Zuyi Yuan,Qingchun Zeng,Xiaodong Li,Yushi Wang,Yan Shu,Mulei Chen,Ling Tao,Xinli Li,Jingfeng Wang,Zaixin Yu,Xiang Cheng,Kui Hong,David Zemanek,Henning Bundgaard,Jens Thune,Morten Jensen,Jens Mogensen,Gilbert Habib,Philippe Charron,Thibault Lhermusier,Jean-Noël Trochu,Patricia Reant,Damien Logeart,Veselin Mitrovic,Tarek Bekfani,Frank Edelmann,Tim Seidler,Benjamin Meder,Paul Christian Schulze,Stephan Stoerk,Tienush Rassaf,Bela Merkely,Donna Zfat-Zwas,Majdi Halabi,Offir Paz,Xavier Piltz,Marco Metra,Marco Canepa,Beatrice Musumeci,Michele Emdin,Ahmad Amin,Christian Knackstedt,Wojciech Wojakowski,Dariusz Dudek,Alexandra Toste,José Mesquita Bastos,Juan Ramón Gimeno Blanes,Rafael Jesus Hidalgo Urbano,Ana Garcia Alvarez,Luis Miguel Rincón Diaz,Tomas Vicente Ripoll Vera,Perry Elliott,Nhs Greater Glasgow,Rob Cooper,Liverpool Heart,Masliza Mahmod,Antonis Pantazis,Maria Teresa Tome Esteban,Oregon Health,Ali Marian,David Owens,Frank McGrew,Richard Bach,Omar Wever-Pinzon,Elias Collado,Aslan Turer,Bashar Hannawi,Jeffrey Geske,Penn Heart,John Symanski,Sanger Heart,Christopher Kramer,Nitasha Sarswat,Ferhaan Ahmad,Jeremy Markowitz,Neal Lakdawala,Sandeep Jani,Marshall Brinkley,Ozlem Bilen,Craig Asher,Sitaramesh Emani,Abhinav Sharma,David Fermin,Melissa Lyle,David Raymer,Andrew Darlington,Christopher Nielsen,Andrew Wang,Sherif Nagueh,Matthew Martinez,Milind Desai,Albree Tower-Rader,Jacob Kelly,Alaska Heart,Florian Rader,Sounok Sen,Patrick Bering,Mathew Maurer,Sumeet Mitter,Mark Sherrid,Timothy Wong,Zainal Hussain,Sara Saberi,Srihari Naidu,Jorge Silva Enciso

DOI: https://doi.org/10.1161/JAHA.124.035993

2024-08-06

Abstract:Background: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). Methods and results: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation. Conclusions: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.
Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

Martin S. Maron,Theodore P. Abraham,Caroline J. Coats,Iacopo Olivotto,Matthew M.Y. Lee,Michael Arad,Nuno Cardim,Chang-Sheng Ma,Lubna Choudhury,Hans-Dirk Düngen,Pablo Garcia-Pavia,Albert Hagege,Gregory D. Lewis,Michelle Michels,Artur Oreziak,Anjali T. Owens,Jacob Tfelt-Hansen,Josef Veselka,Hugh C. Watkins,Stephen B. Heitner,Daniel L. Jacoby,Stuart Kupfer,Fady I. Malik,Lisa Meng,Amy Wohltman,Ahmad Masri

DOI: https://doi.org/10.1016/j.cardfail.2023.11.006

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by myocardial hypercontractility with left ventricular outflow tract obstruction (LVOTO), reduced exercise capacity, and heart failure symptoms. Aficamten is a next-in-class cardiac myosin inhibitor with unique physicochemical properties that appear to safely and effectively reduce LVOTO and improve symptoms and cardiac biomarkers (REDWOOD-HCM; NCT04219826). SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction, Impact of Aficamten in HCM; NCT05186818) is the pivotal Phase 3 trial evaluating the safety and efficacy of aficamten in patients with symptomatic oHCM and objective evidence of reduced functional capacity. Herein we present the baseline characteristics of patients enrolled in SEQUOIA-HCM. Methods SEQUOIA-HCM is an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with symptomatic (NYHA class II–III) oHCM (left ventricular ejection fraction [LVEF] ≥60%; left ventricular outflow tract gradient [LVOT-G] ≥30 mmHg at rest and ≥50 mmHg with Valsalva), and peak oxygen uptake (pVO2) ≤80% of age- and sex-predicted maximum. Patients were randomized (1:1) to either oral placebo or aficamten, with site-based echocardiographic guidance to achieve individualized daily doses of 5, 10, 15, or 20 mg. The primary efficacy outcome is change in pVO2 on exercise testing from baseline to Week 24. Results SEQUOIA-HCM has enrolled 282 patients. Available patient characteristics at baseline are shown in Table 1. The mean (SD) age was 59.1 (12.9) years, 40.8% were female, and 22% were non-white. Baseline New York Heart Association functional class was Class II for 203 patients (72%), Class III for 67 patients (23.8%), and Class IV for 1 patient (0.4%). Just over half of the patients (172; 61%) were treated with beta-blockers. The mean baseline pVO2 was 18.5 (SD 4.5) mL/kg/min or 57.2% of predicted maximum, and the mean Kansas City Cardiomyopathy Questionnaire Clinical Score was 74.7 (SD 18.1). Geometric mean (Q1, Q3) high-sensitivity cardiac troponin I was 16.9 (7.7, 27.2) ng/L. At this time, LVEF, LVOT-G, and N-terminal pro–B-type natriuretic peptide remain blinded measures. Conclusion SEQUOIA-HCM has enrolled a diverse and representative oHCM population with baseline characteristics reflecting significant symptom burden. Results will provide guidance on the utility of aficamten, a next-in-class cardiac myosin inhibitor, in patients with symptomatic oHCM.

cardiac & cardiovascular systems
Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

C J Coats,A Masri,R Barriales-Villa,T P Abraham,B Claggett,A Hagege,C Y Ho,M M Y Lee,M S Maron,A T Owens,J Tfelt-Hansen,H C Watkins,D L Jacoby,A Wohltman,J L Januuzi

DOI: https://doi.org/10.1093/eurheartj/ehae666.2033

IF: 39.3

2024-10-29

European Heart Journal

Abstract:Background Multiple studies show that circulating cardiac biomarkers, N-terminal pro-B type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin I (hs-cTnI) are associated with key pathophysiological processes and clinical outcomes in obstructive hypertrophic cardiomyopathy (oHCM). Herein we describe the impact of aficamten on cardiac biomarkers in SEQUOIA-HCM (NCT05186818). Purpose In this pre-specified analysis, we describe associations between baseline NT-proBNP and hs-cTnI concentrations and assess the relationship between changes after treatment with aficamten and trial endpoints. Methods Patients with oHCM in NYHA Class II-III, were randomized 1:1 to 24 weeks of daily aficamten (5–20 mg, n=142) or placebo (n=140). Aficamten dose was adjusted to achieve Valsalva left ventricular outflow tract gradient (LVOT-G) <30 mmHg while maintaining left ventricular ejection fraction (LVEF) ≥50%. Peak oxygen consumption (pVO2) was measured by cardiopulmonary exercise testing at baseline and week 24. Cardiac biomarkers were measured at baseline, each dose titration (weeks 2, 4, and 6), every 4 weeks during treatment and after 4 weeks drug washout. Multivariable regression analysis was used to identify significant predictors of baseline biomarker values. Joint modeling and mediation analysis was used to determine how much of the treatment effect was indirectly mediated by NT-proBNP and hs-cTnI. Results In 282 symptomatic oHCM patients (mean age 59 years, 41% female), the median (IQR) NT-proBNP was 788 ng/L (346, 1699) and hs-cTnI was 12 ng/L (9, 27). At baseline, LVOT-G modestly correlated with NT-proBNP, rho = 0.26 (p<0.001) but not hs-cTnI, rho = 0.06 (p=0.36). Predictors of baseline biomarker values are summarized in Table 1. Compared to placebo, aficamten treatment was associated with an early relative reduction from baseline at week 8 in NT-proBNP (-79% (95% CI -83%, -76%, p<0.001) and in hs-cTnI -41% (-49%, -32%), p<0.001. This magnitude of change persisted to week 24 with biomarker return to baseline after aficamten washout (Figure 1). The mediation analysis suggested that NT-proBNP reduction over the 24-week treatment period reflected 101% (41%, 195%) of aficamten's effect on pVO2. In contrast hs-cTnI reduction reflected 3% (-18%, 30%) of aficamten's effect on pVO2. Conclusions Concentrations of NT-proBNP and hs-cTnI are associated with clinically relevant echocardiographic variables in oHCM. Compared with placebo, aficamten treatment markedly reduced plasma NT-proBNP and hs-cTnI concentrations, evident from week 2 and persisting until the end of treatment. NT-proBNP reduction may link LVOT-G with reduced exercise capacity in oHCM. These data support the use of biomarkers as a tool for managing patients with oHCM in order to monitor response to aficamten therapy.Effect of aficamten on biomarkersPredictors of baseline biomarkers

cardiac & cardiovascular systems
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial

Matthew M Y Lee,Ahmad Masri,Michael E Nassif,Roberto Barriales-Villa,Theodore P Abraham,Brian L Claggett,Caroline J Coats,Juan Ramón Gimeno,Ian J Kulac,Isabela Landsteiner,Changsheng Ma,Martin S Maron,Iacopo Olivotto,Anjali T Owens,Scott D Solomon,Josef Veselka,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,Gregory D Lewis,SEQUOIA-HCM Investigators,Andrew Wang -,Mark V Sherrid -,Jacob P Kelly -,Ali J Marian -,Anjali Tiku Owens -,Omar Wever-Pinzon -,David Owens -,Matthew T Wheeler -,Sherif F Nagueh -,Florian Rader -,Frank A McGrew -,Timothy Wong -,Thomas O'Neill -,Richard G Bach -,Matthew Martinez -,Neal K Lakdawala -,Elias Collado -,Aslan Turer -,Milind Desai Y -,Zainal Hussain -,Albree F Tower-Rader -,Bashar Hannawi -,Jeffrey Geske -,Sara Saberi -,Dermot Phelan -,Christopher Kramer -,Nitasha Sarswat -,Ferhaan Ahmad -,Lubna Choudhury -,Jeremy S Markowitz -,Sounok Sen -,Patrick Bering -,Martin S Maron -,Sandeep Jani -,Douglas Brinkley -,Srihari Naidu -,Mathew S Maurer -,Noah Moss -,Ozlem Bilen -,Jorge Silva Enciso -,Robert Fraser -,Olakunle Akinboboye -,Craig Asher -,Sitaramesh Emani -,Abhinav Sharma -,David Fermin -,Melissa Lyle -,David Raymer -,Andrew Darlington -,Frederic Resnic -,Christopher D Nielsen -,Marco Metra -,Beatrice Musumeci -,Michele Emdin -,Mattia Targetti -,Marco Canepa -,Michelle Michels -,Christian Knackstedt -,Ahmad S Amin -,Roberto Barriales Villa -,Pablo Garcia Pavia -,Juan Ramon Gimeno Blanes -,Rafael Jesus Hidalgo Urbano -,Luis Miguel Rincon Diaz -,Tomas Vicente V Ripoll Vera -,Ana Garcia Alvarez -,David Zemanek -,MortenK Jensen -,Jens Mogensen -,Jens J Thune -,Henning Bundgaard -,Philippe Charron -,Jean-Noel Trochu -,Gilbert Habib -,Thibault Lhermusier -,Patricia Reant -,Albert A Hagege -,Damien Logeart -,Veselin Mitrovic -,Frank Edelmann -,Tim Seidler -,Benjamin Meder -,Paul Christian Schulze -,Stefan Stoerk -,Tarek Bekfani -,Tienush Rassaf -,Bela Merkely -,Michael Arad -,Majdi Halabi -,Donna Zwas -,Xavier Piltz -,Offir Paz -,Manhal Habib -,Dariusz Dudek -,Artur Oreziak -,Wojciech Wojakowski -,Alexandra M Toste Batista -,Jose Adelino Mesquita Bastos -,Perry M Elliott -,Masliza Mahmod -,Caroline Coats -,Robert Cooper -,William Bradlow -,Antonios Pantazis -,Maria Teresa Tome Esteban -,Shaina McGinnis,Joseph Campain,Diane Cocca-Spofford,Ilya Giverts,Catherine Griskowitz,Chloe Newlands,Fabely Moreno Moreno

DOI: https://doi.org/10.1001/jamacardio.2024.2781

2024-09-04

Abstract:Importance: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac myosin inhibitor, on a comprehensive set of exercise performance and clinical measures. Objective: To evaluate the effect of aficamten on exercise performance using cardiopulmonary exercise testing with a novel integrated measure of maximal and submaximal exercise performance and evaluate other exercise measures and clinical correlates. Design, setting, and participants: This was a prespecified analysis from SEQUOIA-HCM, a double-blind, placebo-controlled, randomized clinical trial. Patients were recruited from 101 sites in 14 countries (North America, Europe, Israel, and China). Individuals with symptomatic obstructive HCM with objective exertional intolerance (peak oxygen uptake [pVO2] ≤90% predicted) were included in the analysis. Data were analyzed from January to March 2024. Interventions: Randomized 1:1 to aficamten (5-20 mg daily) or matching placebo for 24 weeks. Main outcomes and measures: The primary outcome was change from baseline to week 24 in integrated exercise performance, defined as the 2-component z score of pVO2 and ventilatory efficiency throughout exercise (minute ventilation [VE]/carbon dioxide output [VCO2] slope). Response rates for achieving clinically meaningful thresholds for change in pVO2 and correlations with clinical measures of treatment effect (health status, echocardiographic/cardiac biomarkers) were also assessed. Results: Among 282 randomized patients (mean [SD] age, 59.1 [12.9] years; 115 female [40.8%], 167 male [59.2%]), 263 (93.3%) had core laboratory-validated exercise testing at baseline and week 24. Integrated composite exercise performance improved in the aficamten group (mean [SD] z score, 0.17 [0.51]) from baseline to week 24, whereas the placebo group deteriorated (mean [SD] z score, -0.19 [0.45]), yielding a placebo-corrected improvement of 0.35 (95% CI, 0.25-0.46; P <.001). Further, aficamten treatment demonstrated significant improvements in total workload, circulatory power, exercise duration, heart rate reserve, peak heart rate, ventilatory efficiency, ventilatory power, and anaerobic threshold (all P <.001). In the aficamten group, large improvements (≥3.0 mL/kg per minute) in pVO2 were more common than large reductions (32% and 2%, respectively) compared with placebo (16% and 11%, respectively). Improvements in both components of the primary outcome, pVO2 and VE/VCO2 slope throughout exercise, were significantly correlated with improvements in symptom burden and hemodynamics (all P <.05). Conclusions and relevance: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten. Trial registration: ClinicalTrials.gov Identifier: NCT05186818.
Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM

Ahmad Masri,Roberto Barriales‐Villa,Perry Elliott,Michael E. Nassif,Artur Oreziak,Anjali T. Owens,Albree Tower‐Rader,Stephen B. Heitner,Stuart Kupfer,Fady I. Malik,Chiara Melloni,Lisa Meng,Jenny Wei,Sara Saberi,on behalf of the FOREST‐HCM Investigators

DOI: https://doi.org/10.1002/ejhf.3372

2024-07-20

European Journal of Heart Failure

Abstract:Aims The aim of this study was to report safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST‐HCM trial. Methods and results Patients were started on aficamten 5 mg daily, with doses adjusted in 5‐mg increments (5–20 mg) at ≥2‐week intervals according to site‐read left ventricular ejection fraction (LVEF). Aficamten dose was increased if LVEF ≥55%, maintained if LVEF 50–54%, decreased if LVEF 40–<50%, and temporarily interrupted if LVEF <40%. Safety and efficacy were assessed over 36 weeks. Overall, 34 patients were enrolled (mean age 57.2 ± 15.3 years, 62% female, 41% in New York Heart Association [NYHA] class III). Over 36 weeks, 82.3% achieved 15–20 mg daily dose and there was a modest reduction in LVEF by −4.3% ± 5.2 from 70% ± 6.1 (p

cardiac & cardiovascular systems
Selective Interventricular Septal Radiofrequency Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?

Qiang Liu,Hangyuan Qiu,Ruhong Jiang,Xiaomei Tang,Wenpu Guo,Kuangshi Zhou,Qiufan Chen,Yaxun Sun,Lu Yu,Shiquan Chen,Pei Zhang,Xia Sheng,Jun Zhu,Jianwei Lin,Hui Cheng,Yunhe Wang,Bei Wang,Chan Yu,Yankai Mao,Juhong Zhang,Zuwen Zhang,Paul C. Zei,Guosheng Fu,Chenyang Jiang

DOI: https://doi.org/10.3389/fcvm.2021.743044

IF: 3.6

2021-01-01

Frontiers in Cardiovascular Medicine

Abstract:Introduction: Septal mass reduction is beneficial for hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular outflow (LVOT) gradient and symptoms, with surgical myectomy or alcohol septal ablation (ASA) currently recommended in selected patients. Radiofrequency (RF) ablation of hypertrophied septum has been published as a novel method to alleviate LVOT obstruction in small populations. This study aims to investigate factors influencing clinical outcomes of radiofrequency septum ablation. Methods and Results: In this study, 20 patients with HOCM who underwent endocardial ablation were included. Echocardiography and cardiac MRI (CMR) data was collected and analyzed pre- and (or) post- procedure. Nineteen patients underwent ablation successfully, while ablation was aborted in one patient with prior RBBB due to transient complete atrioventricular block (AVB). After 6 months of follow-up, NYHA heart functional class improved from III (2 - 3) to II (1 - 2) (p < 0.001), and resting LVOT gradient was significantly reduced (87.6 ± 29.5 mmHg vs. 48.1 ± 29.7, p < 0.001). LVOT gradient reduction was significantly higher in patients with limited basal septal hypertrophy (60.9 ± 8.3 vs. 27.9 ± 7.1, p = 0.01), shorter anterior mitral leaflet (56.1 ± 6.4 vs. 20.4 ± 5.0, p < 0.01), and normally positioned papillary muscle (36.9 ± 7.1 vs. 75.0 ± 6.3, p < 0.05). Conclusions: Endocardial septal ablation appears to be a safe and effective procedure for alleviating LVOT gradient in patients with HOCM, especially in those with limited basal septal hypertrophy, shorter anterior mitral leaflet, and normal positioned papillary muscle.
Therapeutic Effects of Alcohol Septal Ablation in Mildly Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

P J Li,J,M L Chen,X P Yu,H Zhao,Y C Gao,X L Zhang,T Y Jiang,J Q He

DOI: https://doi.org/10.3760/cma.j.cn112148-20220303-00142

2022-01-01

Abstract:Objective:To observe the therapeutic effects of alcohol septal ablation (ASA) in mildly symptomatic patients (NYHA class Ⅱ) with hypertrophic obstructive cardiomyopathy(HOCM).Methods:This retrospective study included 150 mildly symptomatic patients with HOCM hospitalized in Beijing Anzhen Hospital affiliated to Capital Medical University from March 2001 to December 2017, consisting of medical therapy group ( n=102) and ASA group ( n=48). Baseline clinical data were collected, patients were followed up to a mean of 6.0 (3.5, 8.1) years. Overall and HCM-related mortality events (including chronic heart failure, atrial fibrillation related stroke, sudden cardiac death) were observed in the two groups. Moreover, the improvement of NYHA function classification and left ventricular outflow tract gradient (LVOTG) were also evaluated. Survival analysis was performed by Kaplan-Meier method. Results:Age of this cohort was (52.9±14.5)years, 92 cases(61.3%) were male. In the follow-up, LVOTG was reduced from (85.8±35.4)mmHg (1 mmHg=0.133 kPa) to (27.7±19.8)mmHg ( P<0.001) in the ASA group, and from (66.3±35.0)mmHg to (56.5±27.7)mmHg in medical therapy group( P<0.01). At the last clinical follow-up, there were 32 patients (66.7%) whose LVOTG were<30 mmHg, septal thickness decreased from (20.3±3.8)mm to (16.1±3.4)mm ( P<0.001), NYHA classification was also remarkably improved ( P<0.001). New-onset atrial fibrillation tended to be lower in the ASA group compared to medical therapy group (9.3%(4/43) vs. 20.8%(20/96), P=0.096). Eleven patients (10.8%) in the medical therapy group and 2 patients (4.2%) in the ASA group died during the follow-up. One patient received pacemaker during the peri-procedural period, 1 patient was implanted with two-chamber pacemaker due to Ⅲ° atrioventricular block at 10 years after operation in the ASA group. Survival free of all-cause mortality of ASA group at 5 and 10 years was 97.9% and 97.9%, respectively, which was comparable to the medical therapy group ( P=0.231). Survival free of HCM-related mortality was similar between the two groups ( P=0.397). Conclusions:Compared with medical therapy in mildly symptomatic patients with HOCM, long-term survival rate is similar after ASA. Meanwhile, ASA can remarkably reduce LVOTG and improve the clinical status of the patients. Therefore, ASA may be used as an alternative therapy for mildly symptomatic HOCM patients.
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

Caroline J Coats,Ahmad Masri,Roberto Barriales-Villa,Theodore P Abraham,D Marshall Brinkley,Brian L Claggett,Albert Hagege,Sheila M Hegde,Carolyn Y Ho,Ian J Kulac,Matthew M Y Lee,Martin S Maron,Iacopo Olivotto,Anjali T Owens,Scott D Solomon,Jacob Tfelt-Hansen,Hugh C Watkins,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,James L Januzzi,SEQUOIA-HCM Investigators,Yuhui Zhang,Haibo Yang,Chunli Shao,Zuyi Yuan,Qingchun Zeng,Xiaodong Li,Changsheng Ma,Yushi Wang,Yan Shu,Mulei Chen,Ling Tao,Xinli Li,Jingfeng Wang,Zaixin Yu,Xiang Cheng,Kui Hong,David Zemanek,Henning Bundgaard,Jens Thune,Morten Jensen,Jens Mogensen,Gilbert Habib,Philippe Charron,Thibault Lhermusier,Jean-Noël Trochu,Patricia Reant,Damien Logeart,Veselin Mitrovic,Tarek Bekfani,Frank Edelmann,Tim Seidler,Benjamin Meder,Paul Christian Schulze,Stephan Stoerk,Tienush Rassaf,Bela Merkely,Donna Zfat-Zwas,Michael Arad,Majdi Halabi,Offir Paz,Xavier Piltz,Mattia Targetti,Marco Metra,Marco Canepa,Beatrice Musumeci,Michele Emdin,Michelle Michels,Ahmad Amin,Christian Knackstedt,Artur Oreziak,Wojciech Wojakowski,Dariusz Dudek,Alexandra Toste,José Mesquita Bastos,Pablo Garcia Pavia,Juan Ramón Gimeno Blanes,Rafael Jesus Hidalgo Urbano,Ana Garcia Alvarez,Luis Miguel Rincón Diaz,Tomas Vicente Ripoll Vera,Perry Elliott,Caroline Coats,Rob Cooper,Masliza Mahmod,William Bradlow,Antonis Pantazis,Maria Teresa Tome Esteban,Michael Nassif,Ali Marian,David Owens,Matthew Wheeler,Frank McGrew,Richard Bach,Omar Wever-Pinzon,Elias Collado,Aslan Turer,Bashar Hannawi,Jeffrey Geske,Anjali Owens,John Symanski,Christopher Kramer,Nitasha Sarswat,Ferhaan Ahmad,Theodore Abraham,Jeremy Markowitz,Neal Lakdawala,Lubna Choudhury,Sandeep Jani,Marshall Brinkley,Ozlem Bilen,Craig Asher,Sitaramesh Emani,Abhinav Sharma,David Fermin,Melissa Lyle,David Raymer,Andrew Darlington,Martin Maron,Christopher Nielsen,Andrew Wang,Sherif Nagueh,Matthew Martinez,Milind Desai,Albree Tower-Rader,Jacob Kelly,Florian Rader,Sounok Sen,Patrick Bering,Mathew Maurer,Sumeet Mitter,Mark Sherrid,Timothy Wong,Zainal Hussain,Sara Saberi,Srihari Naidu,Jorge Silva Enciso

DOI: https://doi.org/10.1093/eurheartj/ehae590

2024-09-01

Abstract:Background and aims: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy (oHCM) is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), and to evaluate effect of treatment with aficamten on biomarker concentrations. Methods: Cardiac biomarkers were measured at baseline and serially throughout the study. Regression analyses determined predictors of baseline NT-proBNP and hs-cTnI concentrations, and to evaluate whether early changes in these biomarkers relate to later changes in left ventricular outflow tract gradient (LVOT-G), other echocardiographic measures, health status, and functional capacity. Results: Baseline concentration of NT-proBNP was associated with LVOT-G and measures of diastolic function, while hs-cTnI was associated with left ventricular thickness. Within 8 weeks of treatment with aficamten, NT-proBNP was reduced by 79% (95% CI 83%-76%, P < .001) and hs-cTnI by 41% (95% CI 49%-32%, P < .001); both biomarkers reverted to baseline after washout. Reductions in NT-proBNP and hs-cTnI by 24 weeks were strongly associated with a lowering of LVOT-G, improvement in health status, and increased peak oxygen uptake. NT-proBNP reduction strongly correlated with the majority of improvements in exercise capacity. Furthermore, the change in NT-proBNP by Week 2 was associated with the 24-week change in key endpoints. Conclusions: NT-proBNP and hs-cTnI concentrations are associated with key variables in oHCM. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.
Efficacy of Alcohol Septal Ablation in Mildly Symptomatic or Severely Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

J,P J Li,X P Yu,H Zhao,X L Zhang,C,M D Zhang,T Y Jiang,X T Song,J Q He

DOI: https://doi.org/10.3760/cma.j.cn112148-20220613-00470

2023-01-01

Abstract:Objective:To compare the prognosis of mildly or severely symptomatic patients with obstructive hypertrophic cardiomyopathy (OHCM) who underwent alcohol septal ablation (ASA).Methods:This retrospective study cohort consisted of patients with OHCM who received ASA treatment in Beijing Anzhen Hospital, Capital Medical University from March 2001 to August 2021. These patients were divided into mildly and severely symptomatic groups according to the severity of clinical symptoms. Long-term follow-up was conducted, and the following data were collected: duration of follow-up, postoperatire treatment, New York Heart Association (NYHA) classification, arrhythmia events and pacemaker implantation, echocardiographic parameters, and cause of death. Overall survival and survival free from OHCM-related death were observed, and the improvement of clinical symptoms and resting left ventricular outflow tract gradient (LVOTG) and the incidence of new-onset atrial fibrillation were evaluated. The Kaplan-Meier method and log-rank test were used to determine and compare the cumulative survival rates of the different groups. Cox regression analysis models were used to determine predictors of clinical events.Results:A total of 189 OHCM patients were included in this study, including 68 in the mildly symptomatic group and 121 in the severely symptomatic group. The median follow-up of the study was 6.0 (2.7, 10.6) years. There was no statistical difference in overall survival between the mildly symptomatic group (5-year and 10-year overall survival were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year overall survival were 94.2% and 83.9%, respectively, P=0.405); there was also no statistical difference in survival free from OHCM-related death between the mildly symptomatic group (5-year and 10-year survival free from HCM-related death were 97.0% and 94.4%, respectively) and the severely symptomatic group (5-year and 10-year survival free from HCM-related death were 95.2% and 92.6%, respectively, P=0.846). In the mildly symptomatic group, NYHA classification was improved after ASA ( P<0.001), among which 37 patients (54.4%) were in NYHA class Ⅰ, and the resting left ventricular outflow tract gradient (LVOTG) decreased from 67.6 (42.7, 90.1) mmHg (1 mmHg=0.133 kPa) to 24.4 (11.7, 35.6) mmHg ( P<0.001). In severely symptomatic group, NYHA classification was also improved post ASA ( P<0.001), among which 96 patients (79.3%) improved by at least one NYHA classification, and the resting LVOTG decreased from 69.6 (38.4, 96.1) mmHg to 19.0 (10.6, 39.8) mmHg ( P<0.001). The incidence of new-onset atrial fibrillation was similar between the mildly and severely symptomatic groups (10.2% vs. 13.3%, P=0.565). Cox multivariate regression analysis showed that age was an independent predictor of all-cause mortality in OHCM patients post ASA ( HR=1.068, 95% CI 1.002-1.139, P=0.042). Conclusions:Among patients with OHCM treated with ASA, overall survival and survival free from HCM-related death were similar between mildly symptomatic group and severely symptomatic group. ASA therapy can effectively relieve resting LVOTG and improve clinical symptoms in mildly or severely symptomatic patients with OHCM. Age was an independent predictor of all-cause mortality in OHCM patients post ASA.
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design

Caroline J Coats,Martin S Maron,Theodore P Abraham,Iacopo Olivotto,Matthew M Y Lee,Michael Arad,Nuno Cardim,Chang-Sheng Ma,Lubna Choudhury,Hans-Dirk Düngen,Pablo Garcia-Pavia,Albert A Hagège,Gregory D Lewis,Michelle Michels,Artur Oreziak,Anjali T Owens,Jacob Tfelt-Hansen,Josef Veselka,Hugh C Watkins,Stephen B Heitner,Daniel L Jacoby,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,Ahmad Masri,SEQUOIA-HCM Investigators

DOI: https://doi.org/10.1016/j.jchf.2023.10.004

Abstract:Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening health-related quality of life due to impaired exercise capacity and persistent residual symptoms. Here we consider the design of clinical trials evaluating potential oHCM therapies in the context of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). This large, phase 3 trial is now fully enrolled (N = 282). Baseline characteristics reflect an ethnically diverse population with characteristics typical of patients encountered clinically with substantial functional and symptom burden. The study will assess the effect of aficamten vs placebo, in addition to standard-of-care medications, on functional capacity and symptoms over 24 weeks. Future clinical trials could model the approach in SEQUOIA-HCM to evaluate the effect of potential therapies on the burden of oHCM. (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM [SEQUOIA-HCM]; NCT05186818).
A Modified Endocardial Radiofrequency Ablation Approach for Hypertrophic Obstructive Cardiomyopathy Guided by Transthoracic Echocardiography: a Case Series

Lingqiu Kong,Yongchao Zhao,Hongwei Pan,Jianying Ma,Juying Qian,Junbo Ge

DOI: https://doi.org/10.21037/atm-21-2783

IF: 3.616

2021-01-01

Annals of Translational Medicine

Abstract:Background A series of studies showed that endocardial radiofrequency ablation (ERFA) could reduce the left ventricular outflow tract (LVOT) gradient in patients with septal hypertrophy. This study aimed to determine the safety and efficacy of a modified ERFA approach guided by transthoracic echocardiography (TTE) as an alternative to ablation performed under a three-dimensional (3D) electroanatomical system or intracardiac echocardiography (ICE). Methods Twenty-five patients with hypertrophic obstructive cardiomyopathy (HOCM) underwent ERFA of septal hypertrophy, guided by echocardiography. The LVOT gradient, left ventricular ejection fraction (LVEF), LV thickness, New York Heart Association (NYHA) class, and biochemical laboratory values were recorded before ablation and during follow-up. Results The patients’ peak and stress-induced LVOT gradients were significantly reduced after 12 months of follow-up (resting gradient: from 123.2±17.7 to 15.7±7.8 mmHg, P<0.05; provocative gradient: from 140.2±20.8 to 18.4±8.0 mmHg, P<0.05). Compared with baseline, the septal diameter was reduced slightly after 12 months, but the difference was not significant (24.8±3.5 vs. 24.2±3.4 mm, P>0.05). The reduction in LVOT gradient was associated with an improvement in NYHA functional classification (from 3.0±0.0 to 1.6±0.7, P<0.05), the 6-minute walking distance (413±129 m at baseline; 458±108 m immediately after ERFA; 471±139 m after 12 months, P<0.05), and pro B-type natriuretic peptide levels (from 924.00±139 to 137.45 ±75.73 pg/mL, P<0.05). After the procedure, the patients showed no worsening of LVEF compared with baseline (64%±5.3%), and no cases of bundle branch block nor complete heart block occurred. Conclusions ERFA guided by TTE provides a new treatment option for HOCM which can achieve symptomatic improvement as well as a significant and sustained reduction of the LVOT gradient. Moreover, by avoiding the use of the 3D electroanatomical system or ICE, this treatment has an acceptable cost.
Abstract 19176: Atrial Fibrillation Prevalence With Mavacamten for Obstructive Hypertrophic Cardiomyopathy

likhitesh jaikumar,Monodeep Biswas,Calvin Kagan,Richard S Amara,Kim M Reck,Stephen Shorofsky,Timm Dickfeld,Libin Wang,Vincent Y See

DOI: https://doi.org/10.1161/circ.148.suppl_1.19176

IF: 37.8

2023-11-07

Circulation

Abstract:Introduction: Mavacamten is a first-in-class, small molecule, selective cardiac myosin inhibitor for treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). Partial reversal of hypertrophic remodelng, diastolic dysfunction, and sarcomeric calcium sensitivity have been reported. While atrial fibrillation (AF) prevalence is observed in ~10% of pre-approval study subjects, the effects of mavacamten on AF have not been reported. Hypothesis: AF prevalence remains elevated after mavacamten therapy for HCM Methods: Chart review was performed for standard of care clinical encounters, 12-lead ECG, and echocardiography (TTE) for patients treated mavacamten at a single HCM referral center. Results: Among 12 patients prescribed mavacamten, 92% had no prior AF symptoms nor diagnosis. After 6 months of mavacamten therapy, 25% had AF with 17% new-onset. TTE demonstrated resolution of LVOT gradients in 100% of AF patients at 6 months. Case 1: 60-year-old male with OSA and LVOT gradients of 31 mmHg at rest and 41 mm Hg with Valsalva was started on mavacamten for exertional fatigue and dyspnea. After 3 months, he developed new-onset, paroxysmal AF treated by TEE-guided cardioversion, amiodarone and apixiban. Case 2: 66-year-old female with LVOT gradients of 38 mmHg at rest and 74 mm Hg with Valsalva initiated mavacamten for exertional dyspnea. After mavacamten initiation, exertional symptoms improved but frequent episodes of symptomatic AF persisted despite sotalol 120mg. Case 3: 58-year-old female with LVOT gradient of 97 mm Hg at rest and no change with Valsalva and dyspnea on exertion. After unexplained syncopal events, an implantable cardiac monitor recorded AF. After 1 month of mavacamten, she experienced increased frequency of AF. Conclusions: In a single center experience with mavacamten, AF prevalence of 25% with 17% new onset AF developed despite improvement in symptoms and hypertrophic remodeling parameters. As a novel cardiac myosin inhibitor that attenuates hypertrophic remodeling, diastolic dysfunction, and calcium sensitivity that are anticipated to reduce AF susceptibility, more observation of arrhythmia incidence and burden in larger cohorts will inform arrhythmia outcomes and mechanisms in HCM.

cardiac & cardiovascular systems,peripheral vascular disease
Effect of Mavacamten on Chinese Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: the EXPLORER-CN Randomized Clinical Trial.

Zhuang Tian,Liwen Li,Xiaoyan Li,Jian'an Wang,Qing Zhang,Zhanquan Li,Daoquan Peng,Ping Yang,Wei Ma,Fang Wang,Wei Jin,Xiang Cheng,Jing Sun,Yiqun Fu,Cheng Lyu,Shuyang Zhang

DOI: https://doi.org/10.1001/jamacardio.2023.3030

2023-01-01

JAMA Cardiology

Abstract:Key PointsQuestionWhat is the effect of treatment with mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy? FindingsIn this phase 3 randomized clinical trial of 81 patients, mavacamten significantly improved Valsalva left ventricular outflow tract obstruction compared with placebo and was well tolerated. New York Heart Association functional class, health status, cardiac biomarkers, and cardiac structure were also improved. MeaningThe clinical benefits of mavacamten for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy were consistent with previous data; mavacamten offers a new option for an underrepresented population for whom there is an important unmet medical need. ImportanceMavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking. ObjectiveTo evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM. Design, Setting, and ParticipantsThis phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks. InterventionsPatients were randomized 2:1 to receive mavacamten (starting at 2.5 mg once daily) or placebo for 30 weeks. Main Outcomes and MeasuresThe primary end point was change in Valsalva LVOT peak gradient from baseline to week 30. Left ventricular outflow tract gradients and left ventricular ejection fraction (LVEF) were assessed by echocardiography, while left ventricular mass index (LVMI) was determined by cardiac magnetic resonance imaging. Analysis was performed on an intention-to-treat basis. ResultsA total of 81 patients (mean [SD] age, 51.9 [11.9] years; 58 men [71.6%]) were randomized. Mavacamten demonstrated a significant improvement in the primary end point compared with placebo (least-squares mean [LSM] difference, -70.3 mm Hg; 95% CI, -89.6 to -50.9 mm Hg; 1-sided P<.001). Similar trends were demonstrated for resting LVOT peak gradient (LSM difference, -55.0 mm Hg; 95% CI, -69.1 to -40.9 mm Hg). At week 30, more patients receiving mavacamten than placebo achieved a Valsalva LVOT peak gradient less than 30 mm Hg (48.1% [26 of 54] vs 3.7% [1 of 27]), less than 50 mm Hg (59.3% [32 of 54] vs 7.4% [2 of 27]), and NYHA class improvement (59.3% [32 of 54] vs 14.8% [4 of 27]). Greater improvements were also observed with mavacamten regarding the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (LSM difference, 10.2; 95% CI, 4.4-16.1), N-terminal pro-B-type natriuretic peptide level (proportion of geometric mean ratio, 0.18; 95% CI, 0.13-0.24), high-sensitivity cardiac troponin I level (proportion of geometric mean ratio, 0.34; 95% CI, 0.27-0.42), and LVMI (mean difference, -30.8 g/m(2); 95% CI, -41.6 to -20.1 g/m(2)). Safety and tolerability were similar between mavacamten and placebo. No patients experienced LVEF less than 50%. ConclusionsMavacamten significantly improved Valsalva LVOT gradient vs placebo for Chinese patients. All secondary efficacy end points were also improved. Mavacamten was well tolerated with no new safety signals. This study supports the efficacy and safety of mavacamten in diverse populations, including Chinese patients. Trial RegistrationClinicalTrials.gov Identifier: NCT05174416 This randomized clinical trial evaluates the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy.
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy

Milind Y Desai,Eugene Braunwald

DOI: https://doi.org/10.1016/j.medj.2024.06.001

2024-07-12

Med

Abstract:A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these molecules.

Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial

Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM

Selective Interventricular Septal Radiofrequency Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?

Therapeutic Effects of Alcohol Septal Ablation in Mildly Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

Efficacy of Alcohol Septal Ablation in Mildly Symptomatic or Severely Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design

A Modified Endocardial Radiofrequency Ablation Approach for Hypertrophic Obstructive Cardiomyopathy Guided by Transthoracic Echocardiography: a Case Series

Abstract 19176: Atrial Fibrillation Prevalence With Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Effect of Mavacamten on Chinese Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: the EXPLORER-CN Randomized Clinical Trial.

Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy